As we reflect on the past year, the Neuroendocrine Tumor Research Foundation (NETRF) takes immense pride in the strides we have made towards understanding and
NETRF’s 2023 Margie and Robert E Petersen Neuroendocrine Tumor Research Symposium brought together a hundred of the world’s foremost neuroendocrine cancer scientists in Boston. The
Almost half of patients diagnosed with pancreatic neuroendocrine tumors (PanNETs) have tumors that have spread to their liver, which correlates with poorer outcomes. Given this,
The Neuroendocrine Tumor Research Foundation celebrates a significant milestone in cancer therapy: a first-in-human CAR T cell therapy clinical trial for neuroendocrine tumors (NETs) will
Positive results from the Phase III NETTER-2 trial were reported in September. The NETTER-2 trial is a randomized, multi-center trial evaluating whether Lutathera® plus long-acting
CEO Elyse Gellerman and Director of Patient Education Jessica Thomas joined 400 NET specialists, researchers, and patient advocates in Montreal for the NANETS 2023 Symposium.
Through her 2021 NETRF Investigator Award, Lisa Bodei, MD, PhD, professor of radiology at Weill Cornell Medical College, attending physician and director of targeted radionuclide
United States Congressman Joaquin Castro (TX) joined the NET community in Austin, Texas on September 23rd and shared, for the first time publicly, his personal
NETRF, in partnership with the North American Neuroendocrine Tumor Society (NANETS), is pleased to announce that Iacovos Michael, PhD, Scientist at Sunnybrook Research Institute and
Positive results are reported from the Phase 3 CABINET trial evaluating the drug cabozantinib in advanced neuroendocrine tumors. Interim data shows significant improvement in progression-free
